FDA will put pathogen-agnostic sequencing in front of the Microbiology Devices Panel on November 19, 9 a.m. to 4 p.m. Eastern, at White Oak and on YouTube. The Federal Register notice published September 16 and opened docket FDA-2026-N-8692. The meeting satisfies a requirement in the Food and Drug Omnibus Reform Act of 2022.
The questions are the ones a developer runs into first. How do you build and validate a bioinformatics system when reference sequences change constantly? What does test design look like for a local outbreak versus a national one, and for a pathogen nobody has characterized yet? FDA also wants the panel on implementation and on how the agency should coordinate going forward.
Two deadlines matter, and the later one is the weaker. Comments close November 12 at 11:59 p.m. Eastern, but anything filed after November 3 goes to FDA staff rather than to the panel members who will be in the room. A sequencing diagnostics company with a validation argument to make should work to November 3.
Questions & Answers
When is the FDA Microbiology Devices Panel meeting on pathogen-agnostic sequencing?
The Microbiology Devices Panel meets November 19, 2026, from 9 a.m. to 4 p.m. Eastern at FDA's White Oak campus in Silver Spring, Maryland, with an online YouTube feed. FDA announced it in a Federal Register notice published September 16, 2026.
What is the docket number and comment deadline for the pathogen-agnostic sequencing panel?
The docket is FDA-2026-N-8692. Comments close November 12, 2026 at 11:59 p.m. Eastern, but only comments submitted by November 3, 2026 are provided to the advisory committee itself.
What will the FDA panel on pathogen-agnostic sequencing discuss?
FDA asked the panel to look at the scientific, clinical and public health dimensions of pathogen-agnostic sequencing in emergency preparedness and response, including how to build and validate a bioinformatics system when reference sequences change often, and test design for local and national outbreaks involving known and unknown pathogens.